Athina Ganner

Dr. med.
Principal Investigator
(Associated Member)

Department of Medicine, Renal Division
Medical Center – University of Freiburg
Hugstetter Str. 55
79106 Freiburg

Current Position

Attending Physician

Academic Education

1997 - 2004 Studies in Medicine, Medical University of Vienna and Charité, Universitätsmedizin Berlin

Advanced Qualifications

2012 Board Certification (Facharztprüfung) in Nephrology
2012 Doctoral degree in Medicine (Dr. med.)(summa cum laude), University of Freiburg, Advisor: Prof. Dr. Gerd Walz
2010 Board Certification (Facharztprüfung) in Internal Medicine
2009 Certification (Zusatzweiterbildung) in Emergency Medicine

Postgraduate Positions

2016 - present Attending Physician (Funktionsoberärztin), Department of Medicine, Renal Division, Medical Center - University of Freiburg
2019 – 2021 Brigitte-Schlieben-Lange-Fellowship (Ministerium für Wissenschaft, Forschung und Kunst des Landes Baden-Württemberg)
2014 - 2016 Attending Physician, Department of Medicine and Department of Emergency Medicine, Triemli Hospital, Zürich
2012 - 2014 Attending Physician (Funktionsoberärztin), Department of Medicine, Renal Division, Medical Center - University of Freiburg
2011 - 2012 Attending Physician (Funktionsoberärztin), University Emergency Center - University of Freiburg
2004 - 2011 Research Fellow and Clinical Fellow, Renal Division, Medical Center - University of Freiburg

Link to all publications of Athina Ganner: PubMed

Publications on CRC 1453 funding

Buckley M, Terwagne C, Ganner A, …, Diederichs SNeumann-Haefelin E, Turajlic S, Ivakine EA, Findlay GM. Saturation genome editing maps the functional spectrum of pathogenic VHL alleles. Nat Genet (2024). Pilz JF, Klein M, Neumann-Haefelin EGanner A. VHL-dependence of EHHADH Expression in a Human Renal Cell Carcinoma Cell Line. J Kidney Cancer VHL (2024). Mohl DA, Lagies S, Zodel K, Zumkeller M, Peighambari A, Ganner A, Plattner DA, Neumann-Haefelin E, Adlesic MFrew IJ, Kammerer B. Integrated Metabolomic and Transcriptomic Analysis of Modified Nucleosides for Biomarker Discovery in Clear Cell Renal Cell Carcinoma. Cells (2023). Ganner A, Philipp A, Lagies S, Wingendorf L, Wang L, Pilz F, Welte T, …, Frew IJ, Walz G, Neumann-Haefelin E. SCD5 Regulation by VHL Affects Cell Proliferation and Lipid Homeostasis in ccRCC. Cells (2023). Welte T, Arnold F, Westermann L, Rottmann FA, Hug MJ, Neumann-Haefelin EGanner A. Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study. BMC Nephrol (2023). Ganner A, Gehrke C, Klein M, Thegtmeier L, Matulenski T, …, Walz GFrew IJNeumann-Haefelin E. VHL suppresses RAPTOR and inhibits mTORC1 signaling in clear cell renal cell carcinoma. Sci Rep (2021).